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Abstract
Background: Gout is a chronic disease of monosodium urate (MSU) crystal deposition. Although hyperuricaemia is
the central risk factor for development of gout, not all people with hyperuricaemia have subclinical MSU crystal
deposition or indeed, symptomatic disease. The aim of this systematic literature review was to identify factors that
contribute to MSU crystallization.
Methods: A search was conducted of the electronic databases PubMed, Science Direct and Scopus. Articles were
included if they contained original data related to MSU crystallization. The methods and results were summarized
and categorized into articles describing at least one of the three key steps in MSU crystallization (reduced urate
solubility, nucleation and growth).
Results: A total of 2175 articles were initially identified in our systematic search with 35 of these articles included in
the final analysis. Elevated urate concentration was identified as a central factor driving all three stages of MSU
crystallization. Factors that were found to consistently reduce urate solubility were reduced temperatures, pH 7–9
and various ions including sodium ions. Connective tissue factors including bovine cartilage homogenates and
healthy human synovial fluid and serum all enhanced urate solubility. MSU nucleation was found to be increased
by a number of factors, including sodium ions, uric acid binding antibodies, and synovial fluid or serum from
patients with gout. Other than elevated urate concentrations, no other specific factors were identified as promoters
of MSU crystal growth.
Conclusions: Increased urate concentration is the key factor required at each stage of MSU crystallization. Different
proteins and factors within connective tissues may promote MSU crystallization and may be important for
determining the sites at which MSU crystallization occurs in the presence of elevated urate concentrations.
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Background
Gout is a chronic disease of monosodium urate (MSU)
crystal deposition. The clinical features of gout occur
due to host tissue responses to these crystals [1]. Four
phases or stages of disease have been proposed [2, 3]: A:
asymptomatic hyperuricaemia, without evidence of MSU
crystal deposition; B: asymptomatic hyperuricaemia and
evidence of MSU crystal deposition (by microscopy or
advanced imaging); C: MSU crystal deposition with prior
or current symptoms of acute gout flares; D: advanced
gout (tophi, chronic gouty arthropathy, bone erosion).
Hyperuricaemia is the central risk factor for develop-
ment of gout [4]. However, many people with hyperuricae-
mia do not have subclinical MSU crystal deposition or
indeed, symptomatic disease. For example, a recent dual
energy computed tomography study has shown that only
24 % of asymptomatic individuals with serum urate con-
centrations >9 mg/dL had imaging evidence of MSU crys-
tal deposition [5]. Similar findings have been reported in
ultrasonography studies of individuals with asymptomatic
hyperuricaemia [6–8]. A further important observation is
that MSU crystal deposition occurs preferentially at cer-
tain sites, particularly the 1st metatarsophalangeal joint,
femoral condyle, Achilles tendon, and patellar tendon [9, 10].
Collectively, these data suggest that factors in addition to
urate concentration contribute to MSU crystallization.
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Viewed microscopically, MSU crystals are needle-
shaped with a triclinic structure containing three un-
equal axes, none of which are perpendicular to the
others [11, 12]. At the molecular level, the long axis of a
three-dimensional MSU crystal is made up of sheets of
closely spaced purine rings orientated parallel to the
(011) plane. These sheets are stacked one on top of the
other. Each purine ring contains urate anions aligned
closely together through hydrogen bonding, and water
molecules which are held in place by coordination to
two sodium ions and by one hydrogen bond to the pur-
ine ring. The stacking interactions between the sheets
and interlayer coordination to sodium ions results in
twisting of the urate ion 7.7° out of the (011) plane.
These interactions are required for urate ions to main-
tain octahedral geometry about the sodium ion [11, 12].
In general, three keys steps are required for crystal for-
mation from a liquid mixture [13]; reduced solubility
(leading to supersaturation), nucleation (which involves
formation of clusters of solute molecules that ultimately
reach a critical size and become stable) and crystal growth
(subsequent growth of stable nuclei). Supersaturation
drives both nucleation and growth of crystals, and con-
trols the rate of crystal formation [13]. Using this general
framework of crystal formation, we performed a system-
atic literature review with the aim of identifying factors
that contribute to MSU crystallization in gout.
Methods
A systematic search strategy was formulated to identify fac-
tors that contribute to MSU crystallization. This analysis
was conducted in concordance with Preferred Reporting
Items for Systematic Reviews and Meta-analyses (PRISMA)
guidelines [14]. Electronic searches were performed in the
following online databases: PubMed, Science Direct and
Scopus. The following search keywords were used: “uric”,
“urate”, “crystal*”, “grow*”, “form*”, “precipitat*”, “solub*”
and “nucleat*”. The PubMed database indicated that the
truncation “form*” had over 600 variations and omitted
some search results when this truncation was used. For this
reason, search words used instead of “form*” in the
PubMed search were “form”, “formation”, “forming” and
“formed”. An example of the search strategy is shown in
Fig. 1. Data sources were English publications from these
databases. No date restrictions were used (earliest database
search date was 1946). The search was completed on 1st
December 2014. Articles were included if they contained
original data related to MSU crystallization. Congress ab-
stracts were not searched or included in the current ana-
lysis. Exclusion criteria were: review article with no original
work or data on MSU crystallization; not in English; no
focus on MSU crystallization (e.g. focused on mechanisms
of hyperuricaemia, crystal coating, the inflammatory re-
sponse or renal function); primarily focused on other types
of crystals; or related to uric acid nephrolithiasis or urolith-
iasis. Duplicate articles were removed from the search list.
Articles were then excluded by review of titles and abstracts
by two independent reviewers (AC and GL). For the
remaining articles, the full text was reviewed to identify ar-
ticles that met the inclusion criteria. Bibliographic refer-
ences of individual publications were also identified and
reviewed during this stage (Fig. 2).
Each article that fulfilled inclusion criteria was then
assessed by two independent reviewers (AC and GL). The
methods and results were summarized and categorized
into articles describing one or more of the three key MSU
crystallization steps (solubility, nucleation and growth).
The specific factors assessed (e.g. pH, temperature, con-
nective tissue factors and proteins, concentration of ions,
antibodies, kinetics, crystal morphology and other), and
the types of assay used in each study (in vitro, ex vivo, in
vivo) were recorded.
A quality score was also determined. As a quality score
has not been described for systemic literature reviews of
laboratory studies, we devised the following score
expressed as a number out of 4, determined by the sum of
four questions (each positive answer scored as 1): was
there a clear statement of the aims of the research?; is the
method appropriate for the study aims?; are the results
stated consistent with the results presented? i.e., do the
figures, or data presented support the written results?; and
do the results/data justify the conclusions made?
Results
Search results
Following removal of duplicates, 2175 journal articles were
identified from the three databases searched. Titles were
reviewed and 1688 articles were excluded because the titles
were either not in English, or did not relate to the research
question. Abstracts were then reviewed and further exclu-
sion of articles was performed using the same criteria as
above. From the bibliographic review, 18 additional articles
were identified. In total, a full review of 109 journal articles
was completed independently by the two reviewers. Of
these articles, 35 were identified as original studies related
to gout and MSU crystallization (Figs. 1 and 2). Of those
studies included in the final analysis, 19 investigated urate
solubility, 21 investigated MSU crystal nucleation, and 9 ex-
amined MSU crystal growth (Additional file 1: Table S1).
The type of assay or assays used to assess each
stage of MSU crystal formation is shown in Table 1.
Most studies used in vitro assays involving the
crystallization of MSU from supersaturated solutions
of urate (34 articles). Ex vivo assays generally involved
the addition of synovial fluid or serum from healthy
people or patients with various arthropathies, includ-
ing gout (10 articles). Very few assays were performed
in vivo and these were done in humans (1 article),
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rabbits (2 articles) or mice (1 article). Some studies
used more than one type of assay.
In the quality assessment of included articles, the ma-
jority of articles were given the maximum quality score
of 4. Seven articles were given a score of 3, and one art-
icle was given a score of 2. Those articles with a score of
2 or 3 generally did not fully explain methodology used,
included results in the text that were not presented as
data or images; and/or the results shown did not fully
support or justify the written text or conclusions made.
Four of the articles included in the final analysis were
published within the past two decades (1996–2015), 20 ar-
ticles were published from the previous two decades
(1976–1995), and 11 articles were published prior to 1976.
Factors affecting urate solubility
Solubility is the property of a solid solute to dissolve
in a liquid to form a homogenous solution of the sol-
ute in the given solvent [15]. The saturation concen-
tration of a substance can be obtained experimentally
by determining the maximum amount of the sub-
stance that is soluble at a given temperature [13]. A
supersaturated solution can be obtained by dissolving
more substance than could normally be dissolved by
the solvent by altering the conditions of dissolution,
for example by changing the pH or temperature of
the solution [15].
For this analysis, in the context of MSU crystallization,
those studies that investigated factors that altered urate
concentration (i.e., changed the concentration of solute),
or factors that affected the dissolution of pre-existing
MSU crystals (i.e., changed the saturation point of the
solute) were assigned to the “solubility” category
(Table 1). Using these assay criteria, there were 19 arti-
cles that examined the solubility of MSU. The results
from these articles demonstrated that temperature, pH,
concentration of ions, proteins and various connective
tissue factors all affected the solubility of MSU.
Temperature
Generally two methods were used to determine the
solubility of urate at different temperatures. First, ex-
cess uric acid was dissolved in solutions of sodium
chloride or water at different temperatures and uric acid
Fig. 1 A summary of the search strategy used to identify articles related to the crystallization of MSU and results from database searches
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concentration was measured once equilibrium had been
reached [16–21]. Second, MSU crystals formed on micro-
scope slides were slowly heated using a specialized
temperature-controlled microscope stage and the
temperature at which the crystals dissolved was used to
calculate solubility [18, 22]. Although, this second method
may have underestimated the solubility, as the heating rate
was too fast for equilibrium to be established [21]. In any
case, both methods demonstrated that decreasing temper-
atures led to reduced solubility of urate in sodium chloride
or water solutions. Loeb [19] calculated the solubility of
urate was 6.8 mg/dL at physiological temperature and so-
dium levels, based on in vitro data produced by Allen et
al. [16].
Table 1 The different assays used in studies of MSU crystallization. These criteria were used to categorize each article into one or




Solubility Two different methods were used to measure the solubility of MSU in vitro. The first method involved changing the conditions
of the solvent, or adding specific factors to the solvent and then measuring the change in urate concentration. The second
method measured the maintenance of MSU in crystalline form whereby one or more synthesized MSU crystals (seed crystals)
were added to the solvent and the dissolution of these crystals was measured. The solvents used for both types of assays were
usually solutions of sodium urate or water.
Nucleation Nucleation assays were typically done in supersaturated sodium urate solutions. Various factors were added to the system and
endpoints included whether new crystals formed in the presence of the given factor or change in condition, the time taken to
form new crystals, and measurement of the total weight of crystals formed at the end of the experiment. Any studies that used
MSU seed crystals in the assay for measuring crystal weight were assigned to this category.
Crystal growth Crystal growth assays involved exposing one or more MSU seed crystals to a solution of sodium urate and measuring the rate
of growth of the seed crystals over time and/or the change in length of the crystals. Changes in crystal morphology in the
presence of a given factor were typically examined using microscopy.
Fig. 2 Flow diagram for selection of articles included in the review
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pH
Similar to the temperature experiments, in vitro
methods were used to determine the effect of pH on
MSU solubility. In one method, supersaturated solutions
of sodium urate at different pH levels were left to equili-
brate and uric acid concentrations were used to calculate
solubility. The results from these studies were variable,
but urate solubility was reported to be greater at pH
levels ≤6 or ≥10, with minimal solubility observed at
pH 7–8 [18, 20]. The reason for increased urate solubil-
ity at either very high or very low pH levels may be due
to the different species of urate that existed in these
conditions. Theoretical equations were used to deter-
mine the proportion of uric acid-urate species in solu-
tion at 37 °C at different pH levels [18]. This study
proposed that at low pH levels, fully protonated uric
acid was the main species present, and at higher pH
levels, urate ions were the predominant species present.
The switch of uric acid to its mono-protonated urate
form was further elucidated by x-ray diffraction in 1981
[23]. In this experimental study, supersaturated solutions
of sodium urate at different pH levels were maintained
at 37 °C and the fractions of uric acid, biurate and urate
ions measured. At pH 5.62, a switch occurred whereby
the predominant species present was urate, compared to
pH <5.62 where uric acid was the predominant species
present. At approximately pH 9, urate ions began to
transform to biurate ions [23]. Mono-protonated urate
ions were identified as the ion species incorporated into
MSU crystals at physiological pH levels [12].
Concentration of ions
The most important factor for determining urate solubility
was the presence of excess urate ions within the solution.
In vitro experiments showed that the rate of dissolution of
pre-existing MSU crystals was inversely proportional to
the degree of urate saturation [23, 24]. However, the con-
centrations of other ions present within the solution also
affected urate solubility. Sodium ions reduced urate solu-
bility at physiologically relevant concentrations [16, 17, 20,
25]. Furedi-Molhofer et al. [26] showed that at pH 7.5 and
35 °C, the addition of increasing concentrations of sodium
chloride to undersaturated solutions of sodium urate
caused the phase boundaries of urate solubility to shift to-
wards lower urate concentrations [26]. Other cations, such
as K+, Mg2+, NH4+, Ca2+ and Cu2+ ions, also reduced
urate solubility to varying degrees, although these findings
may have been influenced by changes in pH that were not
always taken into account during analysis [25, 27].
Connective tissue factors and proteins
There was substantial evidence to suggest that factors
derived from cartilage, synovial fluid and serum altered
urate solubility in both in vitro and ex vivo assays.
Acetone dried homogenates of bovine nasal cartilage
markedly enhanced urate solubility at 4 °C, compared to
homogenates derived from heart, liver, brain or kidney
tissue [28]. Further analysis suggested that protein polysac-
charides within the cartilage were responsible for this effect
and that the structural integrity of these proteins was vital
for their effect on urate solubility [28]. Other cartilage
matrix components also altered urate solubility in vitro.
Addition of proteoglycans extracted from porcine cartilage
to supersaturated solutions of sodium urate resulted in in-
creased urate solubility. Similarly to the polysaccharides,
only structurally intact, aggregated proteoglycans enhanced
urate solubility; non-aggregated proteoglycans treated with
enzyme did not change urate solubility [29].
There was conflicting evidence for the direction of the
effect of isolated glycosaminoglycans on urate solubility.
In one study at 37 °C, increasing concentrations of
chondroitin-4-sulphate (63–188 mg/mL) reduced urate
solubility [30]. However, another study that used a simi-
lar concentration of chondroitin-4-sulphate (80 mg/mL)
showed that there was a slight increase in urate solubil-
ity at 4 °C [28]. A third study reported that very low
concentrations of chondroitin-4-sulphate (0.1–0.4 mg/
mL) also slightly increased urate solubility at 37 °C [31].
The different experimental conditions and variation in
the source of chondroitin sulphate used in these experi-
ments made these results difficult to interpret.
Factors derived from other connective tissues such as
plasma and synovial fluid also influenced urate solubility.
Multiple studies examined the effect of synovial fluid from
people with or without arthritis, including gout and
rheumatoid arthritis (RA) [20, 27, 32]. In healthy people,
urate solubility was lower in plasma and synovial fluid
compared to urine [20]. Dialysis of the plasma prior to
completing solubility assays further enhanced the reduc-
tion effect on urate solubility, which suggested that there
was a macromolecule present within plasma that en-
hanced urate solubility, possibly by sequestering urate
[20]. Albumin was one potential macromolecule reported
to influence urate solubility within plasma. Human serum
albumin significantly enhanced urate solubility at 26 °C
and 37 °C [20]. However, other studies reported only very
minor increases in urate solubility with human or bovine
serum albumin at similar or even higher concentrations
[28]. Articles also reported conflicting data regarding the
influence of hyaluronate in determining urate solubility.
One in vitro study reported that low concentrations of
hyaluronic acid slightly enhanced urate solubility [31].
While another study reported that treatment of synovial
fluid with hyaluronase resulted in enhanced MSU solubil-
ity [32], in which case it would be expected that intact
hyluronate reduces urate solubility. In samples from pa-
tients with osteoarthritis, RA or gout, the dissolution of
MSU crystals was generally greater in plasma compared
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to synovial fluid in all groups, with the smallest difference
between plasma and synovial fluid observed within the
gout group [32]. Another study showed that synovial fluid
from one patient with gout had reduced urate solubility to
a greater extent than synovial fluid from one patient with
RA [27].
Factors affecting MSU nucleation
Nucleation is the appearance of new crystals in a system.
Supersaturation alone is not sufficient to cause
crystallization and before crystallization can actually occur,
a number of minute solid bodies or “nuclei” must exist
within the solution to act as centres of crystallization [33].
In MSU crystallization, it was hypothesized that nucle-
ation in vivo occurs after MSU molecules have clustered
together and reached a critical mass or size, whereby they
are stabilized and no longer susceptible to dispersion
forces within the solvent which would normally promote
dissolution [34, 35]. In our analysis, those studies that re-
ported to measure nucleation or precipitation were cate-
gorized into this stage of crystallization. Nucleation assays
were typically done in supersaturated sodium urate solu-
tions and endpoints included whether new crystals formed
in the presence of a given factor or change in condition,
the time taken to form new crystals, and measurement of
the total weight of crystals formed at the end of the ex-
periment (Table 1). Any studies that used MSU seed crys-
tals in the assay for measuring crystal weight were
categorized into “nucleation” rather than “growth”, as
these experiments cannot differentiate between newly
formed crystals and growth of existing seed crystals. Only
those studies that measured crystal length were catego-
rized into the growth section.
Concentration of ions
Highly elevated urate concentrations in vitro were cru-
cial for MSU crystal nucleation, with a greater number
of MSU crystals formed as the concentration of urate in-
creased [12, 36, 37]. In addition, there were other ions
that influenced MSU nucleation. In solutions of super-
saturated sodium urate (10–12 mM), the addition of in-
creasing sodium ions to the solution resulted in a
greater number of MSU crystals formed in a dose-
dependent manner [37]. Similarly, as urate concentration
was reduced, a greater concentration of sodium ions was
required for spontaneous nucleation to occur [36]. At
physiological concentrations, K+, Mg2+ and Cu2+ ions
slightly reduced MSU nucleation (number of crystals
formed after 1 month) [22, 27, 36]. The effect of calcium
ions on MSU nucleation was not clear. It was initially re-
ported by Khalaf et al. [22] and Wilcox et al. [27] that
Ca2+ ions significantly enhanced MSU nucleation [22,
27]. However, the same authors later reported that there
was no change in the number of MSU crystals formed in
a supersaturated solution of sodium urate in the pres-
ence of additional Ca2+ ions, and further analysis re-
vealed that the crystals formed in this case were actually
calcium urate crystals and not MSU crystals [36].
Connective tissue factors and proteins
Given that MSU crystals preferentially form and deposit
on cartilage and are found in biological fluids where there
are multiple different proteins and molecules present, it
seems likely that MSU nucleation in vivo occurs in a pri-
mary heterogeneous manner (induced by foreign parti-
cles). A number of studies reported that synovial fluid
taken from people with gout enhanced MSU crystal nucle-
ation in ex vivo nucleation assays. In particular, addition
of gouty synovial fluid to supersaturated solutions of so-
dium urate resulted in a faster time to appearance of MSU
crystals and a greater total weight of MSU crystals formed,
compared to synovial fluid from healthy people and pa-
tients with RA or other crystal arthropathies [22, 27, 37,
38]. These results were independent of the baseline uric
acid levels in the synovial fluid samples [37]. These find-
ings suggested that there was a factor present in gouty
synovial fluid that acted as a promoter of MSU nucleation
in hyperuricaemic conditions.
Addition of low concentrations of serum (0.25–6 %)
also increased the amount of MSU crystals formed from
supersaturated solutions in vitro [38, 39], although no
differences between gouty versus healthy human serum
have been reported [40]. A more detailed in vitro ana-
lysis suggested that there was a high molecular weight,
heat sensitive protein present in serum that enhanced
MSU crystallization [38]. Human and bovine serum al-
bumin, globulins (particularly γ-globulin) and collagen
type I, all increased MSU nucleation to varying degrees
[38, 41, 42]. Carboxylate groups present on human albu-
min were required for the positive effect of albumin on
MSU nucleation [41].
A number of observations have implicated damaged
cartilage or tissue factors derived from cartilage as pro-
moters of MSU nucleation [43, 44]. In this review, most
studies that investigated the effects of cartilage factors
on MSU crystallization examined changes in urate solu-
bility as an endpoint. Only one study of cartilage factors
met our criteria for a nucleation assay. Perl-Treves et al.
[41] reported that chondroitin sulphate and hyaluronic
acid both had no effect on the time to nucleation in su-
persaturated solutions of sodium urate at pH 8.0 [41].
Antibodies
More recent articles reported the presence of specific uric
acid binding antibodies that promoted MSU crystal nucle-
ation, possibly through stabilization of MSU nuclei [45–
47]. In one study, IgG antibodies were isolated from syn-
ovial fluid from people with gout and other arthropathies
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such as RA and osteoarthritis. In vitro, the antibodies iso-
lated from gouty synovial fluid had a much faster rate of
MSU crystal appearance in nucleation assays compared to
other synovial fluid samples [46]. Another study demon-
strated that IgG antibodies isolated from the serum of rab-
bits injected with MSU crystals significantly increased
nucleation (faster time to appearance of crystals) in super-
saturated sodium urate solutions in vitro. Antibodies iso-
lated from rabbits injected with other types of crystals did
not have the same effect on MSU nucleation and the au-
thors suggested that this indicated high specificity between
the antibody binding sites and the crystal surface, and the
uric acid binding antibodies were acting as nucleating
templates for MSU crystallization [47]. Kanevets et al. [45]
showed that serum collected from mice injected with
MSU crystals contained antibodies that bound to MSU
crystals ex vivo; 85 % of the bound antibodies were IgM
and 14 % were IgG antibodies. Further analysis revealed
that the F(ab’)2 domain and pentameric structure of IgM
antibodies were important for this binding and subsequent
MSU nucleation [45]. While nucleation was not specific-
ally examined in vivo in this study, mice were injected
with uric acid with either uric acid binding antibodies or
control antibodies, and blood uric acid levels were mea-
sured over time as an indirect method for measurement
of MSU crystal formation. From this experiment, the con-
centration of uric acid in the blood was significantly re-
duced post-injection with the uric acid binding antibodies
compared to control antibodies, which suggested that
MSU nucleation had occurred [45].
Other factors
As well as primary nucleation, it is likely that secondary
nucleation also occurs during MSU crystallization. That
is the nucleation of new crystals from already formed
seed crystals [33]. Images of branch points on MSU
crystals obtained by scanning electron microscopy sup-
ported the notion of secondary nucleation [12]. In vitro,
the addition of MSU seed crystals to a supersaturated
solution of sodium urate increased the rate of MSU for-
mation over time in a dose-dependent manner [39, 48].
Lead urate seed crystals also induced MSU nucleation in
vitro [49, 50]. Seed crystals of other types (silica, CPPD
and hydroxyapatite) had no effect on MSU nucleation
[39], suggesting that MSU nucleation is not induced by
all types of particulates, there is some specificity.
Various chemical dyes have also been tested in vitro
for their effects on MSU nucleation. Neutral red dye and
methylene blue both increased time to crystallization in
nucleation assays [21, 23, 51].
Factors affecting MSU crystal growth
Assays that measured the change in length of MSU crys-
tals over time or those that examined the morphology of
MSU crystals grown in the presence of additional factors
were categorized into the “growth” section (Table 1).
Concentration of ions
The rate of MSU crystal growth over time was
dependent on the level of urate saturation [21, 51]. Allen
et al. [16, 17] measured the growth of a single fixed
MSU crystal over time in supersaturated solutions of
urate at different concentrations. In this experiment,
crystal length and time had a linear relationship when
temperature and urate concentration were kept constant.
As the concentration of urate increased, the rate of crys-
tal growth also increased [16, 17]. At the molecular level,
Perrin et al. [39] adsorbed MSU crystals to coverslips
and solutions of supersaturated urate were flowed over
the crystals at physiological pH, temperature and sodium
concentration [12]. Atomic force microscopy was used
to visualize growth on the (010) crystal surface. Solu-
tions with less than 4 mM urate led to dissolution of
MSU crystals, whereas solutions with 4 mM urate re-
sulted in stability, with no further growth of the crystals
and no dissolution. Between 4 and 8 mM urate, consist-
ent growth of crystals was observed. At 7 mM urate,
macroscopic islands approximately 2 μm length ×
175 nm height were observed on the (010) surface.
These islands grew in a direction dependent manner and
the time for incorporation of the island onto the crystal
was dependent on the island size and the level of super-
saturation. This experiment also demonstrated that these
islands were able to re-orientate themselves on the crys-
tal surface if a growth hillock (physical obstruction) was
encountered [12].
Connective tissue factors and proteins
Compared to urate solubility and MSU crystal nucle-
ation, the effects of connective tissue factors and pro-
teins on MSU crystal growth have not been studied
extensively. One study compared the length of MSU
crystals from ex vivo tophus samples to MSU crystals
grown in vitro in the presence of synovial fluid or serum
components [52]. In vitro, MSU crystals grown in the
absence of any additional factors had a wide range of
lengths (93 ± 43 μm); whereas crystals grown in the pres-
ence of human serum or synovial fluid had a much tigh-
ter range of crystal lengths (serum, 35 ± 12 μm; synovial
fluid, 36 ± 10 μm) which was more comparable to sizes
found within tophi (11 ± 3 μm), although still longer.
The addition of γ-globulin produced a tighter range of
crystals lengths, while chondroitin sulphate, α- and β-
globulins, and human serum albumin all resulted in a
wider range of crystal lengths [52]. Human serum albu-
min also increased the thickness of MSU crystals grown
in vitro [41].
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Discussion
This analysis has identified elevated urate concentrations
as the main factor required for the three stages of MSU
crystallization, including reduced urate solubility, MSU
nucleation and MSU crystal growth. Urate solubility was
also shown to be significantly influenced by various ions
including sodium ions, temperature and pH, with colder
temperatures and slightly basic conditions shown to be
the ideal environment for MSU crystallization to occur.
Uric acid binding antibodies, globulins, collagen, lead
and human serum or synovial fluid were all shown to
promote MSU crystallization at the nucleation stage. In-
creased urate concentration was the only factor identi-
fied in this analysis as a specific promoter of MSU
crystal growth (Fig. 3).
It is currently not known why MSU crystals form in
some hyperuricaemic individuals but not others. In pa-
tients with MSU crystal deposition and gout, there must
be other factors present within the serum or joints of
these individuals that promote MSU crystallization in
the presence of elevated tissue urate concentration. In-
deed, some of the studies included in this analysis indi-
cate that the synovial fluid from these patients does
reduce urate solubility and enhance MSU nucleation
[20, 22, 27, 32, 37, 40]. However, the number of samples
assessed was usually small, sometimes with only one pa-
tient sample examined. In addition, for the urate solubil-
ity studies, synovial fluid and serum samples from
healthy individuals were not assessed and compared to
samples taken from patients with gout [27, 32]. There-
fore, it is still not clear whether all human synovial fluid
and serum reduces urate solubility, or if this effect is
specific to synovial fluid and serum taken from patients
with gout or other forms of arthritis. Studies using sam-
ples from a greater number of people, including healthy
individuals, will provide more insight.
High urate concentration was found to be crucial for
driving MSU crystallization at all three stages (reduced
solubility, nucleation and growth). No other factor was
found to influence all three stages of crystallization, al-
though this is not necessarily because no other factor has
a role in each stage, but simply because all other factors
have not been studied as extensively. Most studies investi-
gated changes in urate solubility or MSU nucleation.
While most of the evidence published was very robust
and there was general agreement between studies, there
were some factors tested that have had conflicting re-
sults reported, particularly for connective tissue factors
and proteins, such as glycosaminoglycans, albumin and
hyaluronate [20, 28, 30–32]. Different protein sources,
experimental conditions and methods may account for
these discrepancies. In addition, some concentrations
used in the in vitro assays were quite low or may not
have reflected physiological concentrations; use of higher
concentrations may have led to different results [41].
Most of the studies described in this analysis used in
vitro methods to study MSU crystallization and typically
only investigated one change in condition or factor at a
Fig. 3 Summary of the factors that influenced the three stages of MSU crystal formation, as identified in the systematic literature review
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time. However, in vivo, urate molecules and MSU crystals
are surrounded by connective tissue factors and proteins,
as well as other biological factors, such as complement
proteins (important for the inflammatory response to
MSU crystals) and antibodies. The interactions between
these factors may also have a role in MSU crystal
formation.
The preference for MSU crystals to form on cartilage
surfaces is well documented [44] and joints affected by
previous trauma or osteoarthritis are more likely to be af-
fected by MSU crystal deposition [43]. Consistent with
these clinical observations, many factors and proteins
within connective tissues were found to influence urate
solubility and MSU nucleation. The physical structure of
connective tissues may also influence MSU crystallization
and growth. Histological studies have shown that MSU
crystals are present within the joint aligned to collagen fi-
bres within the tendon in a highly organized manner [53].
Similarly, crystals identified within cadaveric cartilage from
a patient with gout using scanning electron microscopy
were arranged in specific bow-shaped bundles [54]. In the
current review, the addition of various connective tissue
factors and proteins to in vitro growth assays was shown to
influence MSU crystal lengths [41, 52], although the direc-
tion of these effects were difficult to interpret as the main
focus of these studies was to determine the variation in
crystal lengths with these additional factors, rather than
whether or not these factors were specifically promoting or
inhibiting MSU crystal growth. Collectively, these findings
suggest that the physical environment in which MSU
crystallization occurs may influence growth patterns.
In vitro studies have shown that urate solubility is low-
est in slightly basic conditions [18, 20]. This seems
somewhat contradictory to the clinical observation that
cartilage surfaces are slightly acidic in osteoarthritic
joints, and these surfaces become more acidic as cartil-
age destruction progresses [55]. At the reported pH of
human osteoarthritic cartilage (pH 5.5–6.2) [55], urate
solubility is actually still very low and mono-protonated
urate ions remain the predominant species present
within this pH range [23], suggesting that MSU
crystallization does still occur in these slightly acidic
conditions. In addition, enzymes such as cathepsin K are
specifically activated at lower pH values and lead to fur-
ther degradation of cartilage in osteoarthritic joints [55–
57]. This increased enzyme activity is likely to result in a
local increase in matrix breakdown products which may
serve as MSU crystal nucleation sites, further promoting
MSU crystallization at sites of osteoarthritis. A system-
atic analysis of the effect of cartilage tissue and specific
cartilage factors on MSU nucleation would provide more
insight as to why MSU crystals preferentially form and
deposit on cartilage surfaces, particularly those affected
by osteoarthritis.
One of the most interesting findings of this review has
been that very few studies related to MSU crystallization
have been published in the last 20 years. This result sug-
gests that research into the crystallization of MSU has
not been an active area of gout research in recent times.
The continuation of this work using more recent ad-
vanced imaging technologies and laboratory methods
will be of great benefit to further improve our knowledge
of why and how MSU crystallization occurs in patients
with gout.
Conclusion
In this systematic literature review of factors involved in
the crystallization of MSU, elevated urate concentration
was consistently identified as the key factor required for
all three stages of MSU crystallization. Other factors
shown to be important for controlling urate solubility
included sodium ions, colder temperatures and slightly
higher pH levels. Increased MSU nucleation has been re-
ported in the presence of human serum or synovial fluid
and various isolated connective tissue proteins. Other
than locally increased urate concentrations, no add-
itional factors were identified as specific promoters of
MSU crystal growth. Further research examining the
role of connective tissues in MSU crystallization will ul-
timately enhance our understanding of the biological
basis of gout and may give insight into why only a subset
of people with hyperuricaemia eventually develop gout.
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